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Summary
Objective: To study the effects of the non-steroidal anti-inﬂammatory drugs (NSAIDs) aceclofenac, piroxicam, tenoxicam and indomethacin on
cytokine, matrix metalloproteinases (MMPs), tissue inhibitors of metalloproteinases (TIMPs) and prostaglandin E2 (PGE2) production, by in-
terface membranes (IFT), obtained at revision surgery for aseptic loosening of total joint arthroplasty. Involvement of these soluble factors is
well documented and probably, a pharmaceutically induced inhibition of them might retard loosening.
Methods: IFTs from 10 patients with a loose hip or knee endoprosthesis were collected. The possibility of septic loosening was thoroughly
excluded by histopathologic and microbiologic evaluation. IFTs were cultured in the absence or presence of the tested drugs and the levels
of the soluble mediators were determined, using electrophoretic and enzyme-linked immunosorbent assay techniques. Paracetamol was used
as neutral drug.
Results: All NSAIDs exhibited a pronounced inhibitory effect upon the production of interleukin-6 (IL-6) and tumour necrosis factor-a (TNF-a).
This speciﬁc effect on IL-6 is reported in the literature for the ﬁrst time. The majority of NSAIDs also induced the production of IL-1b in an
adequate portion of samples. These drugs did not have a clear effect on MMP synthesis, but they had a stimulatory tendency on TIMP-1 pro-
duction. Paracetamol, signiﬁcantly decreased the synthesis of TNF-a and that of the gelatinases.
Conclusion: Our in vitro results are encouraging, since it appears that the action of NSAIDs, globally considered, may be beneﬁcial upon the
loosening process. The inhibitory effect of paracetamol upon TNF-a and gelatinases is intriguing. Our data, if supported by similar observa-
tions, probably justify performance of long-term clinical trials.
ª 2006 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
Key words: Arthroplasty, Periprosthetic loosening, Non-steroidal anti-inﬂammatory drugs, Cytokines, Matrix metalloproteinases, Tissue inhib-
itors of matrix metalloproteinases.
International
Cartilage
Repair
SocietyIntroduction
For at least four decades, a lot of research has been done,
in order to elucidate the pathogenetic mechanisms of peri-
prosthetic loosening. Today, it is well known that loosening
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Received 28 April 2006; revision accepted 6 November 2006.53and periprosthetic osteolysis result from the combined ef-
fect of mechanical and biological factors1.
The mechanical factors are related to the type of implants
and the ﬁxation techniques. The biological factors have
been thoroughly investigated. The production of particles
from the implants is the critical event for all biological mech-
anisms to begin1. Also stainless steel particles from surgical
instrumentation can be present in the artiﬁcial joint, even
before skin closure2. The most important and biologically ef-
fective are those generated from the attrition of polyethyl-
ene. Signiﬁcant information has been accumulated about
the mechanisms of particle production, as well as their
shape and size3e5.
These implant particles evoke a foreign-body reaction,
activating macrophages, ﬁbroblasts, T-cells and endothelial1
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terleukin-6 (IL-6), IL-1b, tumour necrosis factor-a (TNF-a)
and Platelet-derived growth factor, prostanoids (especially
prostaglandin E2 (PGE2)) and proteolytic enzymes, mainly
metalloproteinases of the extracellular matrix (MMPs)1,6e8.
These cell products cause, through complex mechanisms,
periprosthetic osteolysis that exceeds the reparative capac-
ity of the ﬁbrous and osseous tissues, resulting in loosening
of the implant2. The role of all these factors in periprosthetic
bone resorption is now well documented2.
MMPs such as interstitial collagenases (MMP-1 and
MMP-13), gelatinases (MMP-2 and MMP-9) and stromely-
sin (MMP-3) are implicated in periprosthetic loosening pro-
cesses, through their ability to degrade the extracellular
matrix components. In particular MMP-1 and MMP-13
may play an important role as initiators of connective tissue
remodelling, since they degrade native type-I and type-III
collagens9e11. They may directly contribute to bone resorp-
tion, by removing the osteoid layer from calciﬁed bone, facil-
itating the osteoclastic bone resorption12. Although tissue
inhibitors of MMPs, such as tissue inhibitors of metallopro-
teinase (TIMP)-1 and TIMP-2, have been detected in peri-
prosthetic tissues, it has been previously reported that
periprosthetic tissue extracts exhibit high TIMP-free collage-
nolytic activity1,13,14.
IL-1b induces differentiation and proliferation of osteo-
clasts as well as the production of MMPs and PGE2 from ﬁ-
broblasts and synovial cells15,16. It also reduces the
osteocalcin production by the osteoblasts17. According to Jir-
anek et al., IL-1bmight play a signiﬁcant role in the formation
of interfacemembrane (IFT), because of its stimulatory activ-
ity on ﬁbroblasts6. Kusano et al. have shown that IL-1b aug-
ments bone resorption in mouse calvaria culture in vitro, by
inducingMMP-2, MMP-3,MMP-9 andMMP-13 production18.
IL-6 is strongly implicated in bone catabolism. It is pro-
duced by the osteoblasts and induces bone resorption19.
It also stimulates the formation of osteoclast-like cells in
long-term human marrow cultures20. In periprosthetic tis-
sues from loose orthopaedic implants with osteolysis, IL-6
levels are much higher than in tissues from loose implants
without bone loss7.
TNF-a also has a catabolic effect on bone. It can up-reg-
ulate bone resorption in cultured mouse calvaria by a pros-
taglandin-independent mechanism and stimulates
osteoblasts to produce osteo-resorptive factors such as
IL-6 and PGE2
21,22. Similar to IL-6, high levels of TNF-
a have been detected in periprosthetic tissues of loose en-
doprostheses with focal osteolysis7. It has also been shown
to exhibit a synergistic effect with titanium particles, when
added in osteoblast culture23.
The role of prostaglandins in mediating pseudomem-
brane associated bone resorption is questionable. It is pro-
posed from in vitro studies that prostaglandins play an
important role in bone resorption24. Periprosthetic tissue,
cultured in the presence of indomethacin, showed less
bone resorptive capacity24. Other investigators have shown
that conditioned media from pre-dialysed periprosthetic
tissue cultures maintained their ability to cause bone re-
sorption, indicating that the prostaglandins, removed by
dialysis, had no effect whatsoever upon bone resorption25.
Therefore, prostaglandins may be implicated in the loosen-
ing process through complex mechanisms involving MMPs
and cytokines2.
Although the inﬂuence of several non-steroidal anti-in-
ﬂammatory drugs (NSAIDs) upon the expression and pro-
duction of most of the factors, mentioned above, by cells
has been thoroughly studied, little information is availablein the literature about their possible role in retarding the
periprosthetic loosening and bone resorption process. The
latter comes from the studies by Herman et al.26 and by Oh-
lin and Lerner27. The results of the ﬁrst suggested that pir-
oxicam, in addition to its expected strong suppressive
effect on PGE2 production, exerted a similar effect upon
TNF-a production by IFTs and that this might have been re-
sponsible for the observed reduction of bone resorbing ac-
tivity. On the contrary that drug showed no consistent effect
on the level of IL-1 expression. Ohlin and Lerner found that
indomethacin or structurally unrelated NSAIDs were able to
alter the bone resorbing activity in the conditioned media of
cultured periprosthetic tissues27. On the other hand, ex-
tended information is available regarding the action of sev-
eral NSAIDs upon signiﬁcant for the loosening process
effector molecules, which though originates from in vitro
studies with articular chondrocytes and synovial or dental
pulp ﬁbroblasts. Ito et al. indicated that indomethacin and di-
clofenac, through inhibition of PGE2, augment the IL-1-in-
duced MMP-9 production in rabbit articular
chondrocytes28. They suggested that these drugs have
a possible deleterious effect on articular cartilage, when
used therapeutically in patients with arthritis. It has been
also reported that indomethacin enhances the IL-1 and
TNF-a-induced production of MMP-129e31. Yamazaki et al.
reported that 40-OH-aceclofenac, the major metabolite of
aceclofenac, inhibits the production of proMMP-1 and
proMMP-3 from synovial cells of patients with rheumatoid
arthritis32. The same investigators, in a subsequent publica-
tion, concluded that 40-OH-aceclofenac suppresses the
IL-1b-induced production of MMP-1 and MMP-3 in rabbit
articular chondrocytes and synoviocytes, independently of
PGE2 inhibition, and has a cartilage-regenerative effect by
inducing glycosaminoglycan production33.
In the present study, we tested the effect of four widely
used NSAIDs, i.e., aceclofenac, piroxicam, tenoxicam and
indomethacin on cytokine, MMP, TIMP and prostanoid pro-
duction by IFTs from patients with aseptic loosening of total
arthroplasty, in order to elucidate their role in the above
mentioned process.
Materials and methods
BIOLOGIC MATERIALS AND CULTURES
IFTs were collected from 10 female patients with mean
age of 67.2 years (range 46e84 years) undergoing revision
for aseptic loosening of total hip or knee arthroplasty. Seven
patients had a loose hip arthroplasty, cemented in ﬁve, of
whom four with cystic osteolysis and two with cup protru-
sion, whereas three had a loose cemented knee arthro-
plasty. Operative intervention occurred at a mean of 12.1
years following initial arthroplasty (range 1e20 years).
The patients had not used any NSAID, for at least 2 weeks
preoperatively.
Immediately after harvesting, part of the specimens was
subjected to histopathological evaluation, followed by ap-
propriate bacteriologic cultures, in order to exclude the pos-
sibility of septic loosening.
The remainder was dissected out from fat, bone particles
and cement (if the primary arthroplasty was cemented),
washed from contaminating blood and minced into
approximately 5 mm3 segments in an aseptic manner. The
segments were randomly mixed and suspended in
Dulbecco’s modiﬁed Eagle’s minimum essential medium
(DMEM), supplemented with 10% heat inactivated foetal
calf serum (FCS), penicillin (100 U/ml) and streptomycin
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weight. The plates were then incubated for 72 h at 37C un-
der 5% CO2, in the presence or absence (control samples)
of the tested NSAID in concentrations corresponding to rec-
ognized therapeutic plasma levels34, i.e., aceclofenac (4
and 10 mg/ml), piroxicam (3 and 10 mg/ml), tenoxicam (6
and 13 mg/ml), and indomethacin (0.5 mg/ml). Paracetamol
(10 mg/ml) was used as ‘‘neutral-control’’ drug, based on
the assumed inability to inhibit cyclooxygenase activity, in
contrast to the NSAIDs. Each drug concentration was
tested in triplicate. At the end of the incubation period, tis-
sue suspensions were centrifuged (10,000g at 4C for
20 min) and the conditioned media were collected and
stored at 20C until further usage. Furthermore, the net
wet weight of the residual tissue was determined.
DETERMINATION OF CYTOKINES LEVELS BY SANDWICH
ENZYME-LINKED IMMUNOSORBENT ASSAY (ELISA)
The levels of IL-1b, IL-6 and TNF-a in conditioned media
were determined by sandwich ELISA, using a matched pair
of monoclonal antibodies, according to the manufacturer’s
instructions (ENDOGEN, Inc., Woburn, MA, USA).
Polystyrene plates (GREINER, Germany) were coated
with capture antibody 2.5 mg/ml for IL-1b and IL-6, and
4 mg/ml for TNF-a in 10 mM phosphate buffer, pH 8.0/
0.14 M NaCl (100 ml/well), overnight at room temperature.
Empty sites in plates were blocked with 4% bovine serum
albumin (BSA) in 10 mM phosphate buffer, pH 7.4/0.15 M
NaCl (phosphate buffered saline (PBS)), (200 ml/well), for
1 h at 37C. After washing three times with 50 mM TriseHCl
buffer, pH 8.0/0.15 M NaCl/0.2% Tween 20 (TBS-T), the
standards or samples, directly or after dilution in PBS,
were added (100 ml/well), and the plates incubated at
37C for 1.5 h in the case of IL-1b and IL-6, and at 4C
for 20 h in the case of TNF-a. After washing three times
with Tris buffer saline-Tween 20 (TBS-T), the biotin-labelled
detecting antibody (0.5 mg/ml) in PBS (100 ml/well) was
added and the plates further incubated for 1.5 h at 37C.
The plates were washed again with TBS-T, and streptavi-
din-peroxidase conjugated at dilution 1:4000 in PBS was
added (100 ml/well) and they were kept at room temperature
for 40 min. After washing twice with TBS-T and once with
0.1 M citrate buffer, pH 5.0, the peroxidase substrate
(0.03% H2O2, 2 mg/ml o-phenyl-diamine in 0.1 M citrate
buffer, pH 5.0) was added (100 ml/well) and the plates
were kept in the dark at room temperature for 30 min. The
reaction was stopped by addition of 2 M H2SO4 (100 ml/
well) and the absorbance at 492 nm was measured.
The concentration of each cytokine was estimated using
a standard curve, constructed with standard solutions of
human recombinant IL-1b, IL-6 and TNF-a (ENDOGEN, Inc.,
Woburn, MA, USA). The sensitivity of the method was
estimated to be 1 pg/ml for IL-1b and IL-6 and 5 pg/ml for
TNF-a. The relationship between absorbance at 492 nm
and concentration was linear from 10 to 400 pg/ml for
IL-1b and IL-6 and from 25 to 1000 pg/ml for TNF-a.
All samples were tested in duplicate.
DETERMINATION OF PGE2 LEVELS BY COMPETITIVE ELISA
The levels of PGE2 in conditioned media were deter-
mined by competitive ELISA, using speciﬁc kits purchased
from Cayman Chemical Co. (Ann Arbor, MI, USA) accord-
ing to the manufacturer’s instructions. The concentration
of PGE2 was estimated using an inhibition curve,
constructed with standard solutions of PGE2 (CaymanChemical Co.). The sensitivity of the method was estimated
to be 10 pg/ml and the relationship between absorbance at
492 nm and concentration was linear from 30 to 250 pg/ml.
Each assay was performed in duplicate.
DETERMINATION OF GELATINOLYTIC (MMP-2 AND MMP-9)
ACTIVITY BY GELATIN ZYMOGRAPHY
The inﬂuence of the NSAIDs on gelatinolytic activity was
estimated, using the gelatin zymography technique as pre-
viously described14. In brief, samples of conditioned media
were pre-incubated at 37C for 15 min in Laemmli sample
buffer and then subjected to Sodium dodecyl sulphate-poly-
acrylamide gel electrophoresis under non-reducing condi-
tions on 10% polyacrylamide gels, containing 1 mg/ml
gelatin35. After washing twice with 50 mM TriseHCl, pH
7.5/5 mM CaCl2/1 mM ZnCl2/0.02% NaN3 buffer, containing
2.5% Triton X-100, and once with the same buffer contain-
ing 0.1% Triton X-100, the gels were incubated at 37 C for
20 h in the same buffer. After staining with Coomassie bril-
liant blue R-250 and destaining of the gels, they were kept
in 7% acetic acid. The molecular mass of each lysis band
was determined, using markers of known molecular mass,
subjected to electrophoresis in parallel. The enzymatic ac-
tivity was veriﬁed by computer analysis of the intensity of
each gelatin lysis band. Gels were scanned on a digital
scanner (Hewlett Packard, ScanJet 6100 C/T), using the
software Corel Photo Paint 7 and the image processing
took place with the Image PC software36. The speciﬁc
MMP-2 and MMP-9 activity was expressed in arbitrary units
(pixels) per gram of wet weight of IFT.
All samples were run in duplicate.
DETERMINATION OF MMP-1, MMP-3, MMP-13 AND TIMP-2
LEVELS BY INDIRECT ELISA
Samples of conditioned media were enriched in MMP and
TIMP by precipitation with (NH4)2SO4 (60% saturation). The
precipitates were dissolved in water (50 ml per sample) and
the resulting solutions were coated on polystyrene plates
by drying overnight at 60C. The empty sites were blocked
with 4% BSA or 4% gelatin (in the case of MMP-13), in
PBS-T (10 mM phosphate buffer, pH 7.2/0.15 M NaCl/
0.05% Tween 20) (200 ml/well) at 37C for 1 h. After washing
twice with PBS-T, polyclonal antibodies (Chemicon, Teme-
cula, CA, USA) against human MMP-1, MMP-3, MMP-13 or
TIMP-2 in PBS-T, containing 0.1% BSA or gelatin, were
added (100 ml/well) and the plates were incubated at 4C
for 20 h. After washing three times with PBS-T and adding
peroxidase-conjugated second antibody (goat anti-rabbit Im-
munoglobulin G) (Chemicon) at dilution 1:4000 in PBS-T/
0.1% BSA or gelatin (100 ml/well), the plates were incubated
for 1 h at 37C. Then, they were washed twice with PBS-T
and once with 0.1 M citrate buffer, pH 5.0, the peroxidase
substrate (0.03% H2O2, 2 mg/ml o-phenyleno-diamine in
0.1 M citrate buffer, pH 5.0) was added (100 ml/well) and they
were kept in the dark for 30 min. The reaction was stopped
by addition of 2 M H2SO4 (100 ml/well) and the absorbance
was measured at 492 nm. Each blank, containing the same
amount of conditioned medium as the respective sample,
was treated in the same manner but was incubated only with
the secondantibody.Eachassaywasperformed in duplicate.
The concentration ofMMPs and TIMP-2was estimated using
standard curves, constructed with standard solutions of hu-
man recombinantMMPs andTIMP-2 (Chemicon). The sensi-
tivity of the method was estimated to be 1 ng/well for MMP-1,
MMP-3 and TIMP-2, and 0.1 ng/well for MMP-13. The
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tion was linear from 2 to 20 ng/well for MMP-1, MMP-3 and
TIMP-2, and from 0.5 to 2 ng/well for MMP-13.
Each assay was performed in duplicate.
The speciﬁcity of the method was tested by immuno-
blotting of IFT culture conditioned media, using the above
mentioned polyclonal antibodies against MMP-1, MMP-3,
MMP-13 and TIMP-2 (Fig. 1), as previously described14.
Only two immunoreactive bands of molecular mass 52 and
42 kDa were detected by anti-MMP-1 antibodies, corre-
sponding to proenzyme and active form of MMP-1, respec-
tively [Fig. 1(A)]. Two major immunoreactive bands of
molecular mass 58 and 54 kDa, and two minor ones of mo-
lecular mass 47 and 44 kDa were detected by anti-MMP-3
antibodies. The major corresponded to the glycosylated
and unglycosylated species of proMMP-3, whereas the mi-
nor to the respective active forms [Fig. 1(B)]. Two immuno-
reactive bands of molecular mass 60 and 50 kDa were also
detected by anti-MMP-13 antibodies, corresponding to pro-
enzyme and the active form of MMP-13, respectively
[Fig. 1(C)]. The anti-TIMP-2 antibodies recognized only
one band of molecular mass 21 kDa [Fig. 1(D)].
DETERMINATION OF TIMP-1 LEVELS BY COMPETITIVE ELISA
Determination of TIMP-1 was performed by a competitive
ELISA. The plates were coated with TIMP-1 0.1 mg/ml in
10 mM phosphate buffer, pH 7.4/0.15 M NaCl (40 ml/well)
by drying overnight at 60C. The empty sites were blocked
with 4% BSA in PBS-T (200 ml/well) at 37C for 1 h and then
the plates were washed twice with PBS-T. Samples of con-
ditioned media were precipitated by ethanol (5 volumes),
the precipitates dissolved in 100 ml of 10 mM Na2EDTA,
pH 3.5 and incubated at 37C for 30 min, in order to disso-
ciate the complexes between TIMP-1 and MMPs37. After
neutralization of samples by addition of 0.1 M Tris solution,
they were mixed with equal volume of polyclonal antibodies
against human TIMP-1 (1:1000 dilution) in PBS-T/0.1%
BSA and pre-incubated at room temperature for 2 h. They
were then added to the wells (100 ml/well) and the
Fig. 1. Representative western blotting of an IFT culture condi-
tioned medium, using polyclonal antibodies against human MMP-
1 (A), MMP-3 (B), MMP-13 (C) and TIMP-2 (D). Markers of known
molecular mass are shown to the right.incubation was further continued for 20 h at 4C. The next
steps were as above described for the indirect ELISA.
The concentration of TIMP-1 was estimated using an inhibi-
tion curve, constructed by standard solutions of recombi-
nant human TIMP-1. The sensitivity of the method was
estimated to be 0.5 ng/well and the relationship between
absorbance at 492 nm and concentration was linear from
0.5 to 4 ng/well.
Each assay was performed in duplicate.
RESULTS PROCESSING AND STATISTICAL ANALYSIS
The results obtained from the applied ELISA were ex-
pressed in mass units per gram of wet weight of IFT,
whereas the speciﬁc MMP-2 and MMP-9 activity from the
zymography was expressed in arbitrary units (pixels) per
gram of wet weight of IFT. Then the ratio mean D/mean C
[where mean D and mean C are the means of the above
values obtained from treated (drug) and untreated (control)
samples, respectively] was calculated, so that the effect of
each drug was presented in relation to control. Ratio <1
or ratio >1 indicated inhibition or induction, respectively.
The percent inhibition or induction, caused by each drug,
was calculated by multiplying (1 ratio) or (ratio 1) by
100, respectively. According to the data obtained, as de-
scribed, graphs were constructed and presented in the ﬁg-
ures in the Results section.
Statistical analysis of the results was performed by Stu-
dent’s non-paired t test. The differences between untreated
(controls) and treated (drugs) samples were considered sta-
tistically signiﬁcant when P< 0.05.
Results
EFFECT OF NSAIDs ON CYTOKINE (IL-1b, IL-6 AND TNF-a)
PRODUCTION
IFTs were cultured in the absence or presence of the
tested NSAIDs and the levels of IL-1b, IL-6 and TNF-
a were determined in the conditioned media (Fig. 2).
As it can be seen [Fig. 2(A)], aceclofenac signiﬁcantly in-
duced the production of IL-1b in four (range 28e52%, mean
35.5%) and ﬁve (range 21e69%, mean 41%) of nine exper-
iments at the low and the high concentrations, respectively.
No signiﬁcant inhibition was observed at any concentration
of the drug. Piroxicam had a signiﬁcant stimulatory effect in
two (range 26e108%, mean 67%) and three (range
19e200%, mean 87.7) of eight cases at the low and the
high concentrations, respectively. Signiﬁcant inhibition
was not observed at any concentration. Tenoxicam ex-
hibited a signiﬁcant stimulatory effect in two (range
28e40%, mean 34%) and four (range 28e100%, mean
60%) of eight cases at the low and the high concentrations,
respectively. It is remarkable that tenoxicam was the only
drug that caused a statistically signiﬁcant inhibition in two
of eight cases at both concentrations (range 20e41%,
mean 30.5%) and (range 23e52%, mean 37.5%) at the
low and the high concentrations, respectively. Indomethacin
signiﬁcantly induced IL-1b in two of eight cases (range
28e45%, mean 36.5%) and inhibited the cytokine in an-
other case (37%). Paracetamol exhibited a signiﬁcant stim-
ulatory effect only in one of the eight cases (80%).
Contrary to the above, a deﬁnite and pronounced inhibi-
tory effect upon IL-6 [Fig. 2(B)] and TNF-a [Fig. 2(C)] pro-
duction was exerted by all the tested NSAIDs in a high
portion of the samples.
Aceclofenac down-regulated the IL-6 expression in six
and seven of 10 assays at the low (range 16e36%, mean
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Fig. 2. Levels of IL-1b (A), IL-6 (B) and TNF-a (C) in conditioned
media obtained from 3-day explant cultures of IFT from hip (circle
symbols) or knee (square symbols) arthroplasty, in the absence
or presence of drugs. Closed symbols represent a statistically sig-
niﬁcant difference between NSAID exposed and unexposed cul-
tures (P< 0.05). Ace1 and 2: aceclofenac at concentrations 4
and 10 mg/ml, respectively; Pir1 and 2: piroxicam at concentrations
3 and 10 mg/ml, respectively; Ten1 and 2: tenoxicam at concentra-
tions 6 and 13 mg/ml, respectively; Ind: indomethacin at concentra-
tion 0.5 mg/ml and Par: paracetamol at concentration 10 mg/ml.25.3%) and the high (range 10e48%, mean 28.2%) con-
centrations, respectively, whereas it up-regulated the IL-6
expression in one of the 10 assays, 28% and 39% at the
low and the high concentrations, respectively. Piroxicam
down-regulated the expression of IL-6 in ﬁve of nine assays
at both concentrations (range 20e32%, mean 26.6%) and
(range 29e57%, mean 43.8%) for the low and the high con-
centrations, respectively. Tenoxicam down-regulated the
expression of IL-6 in ﬁve and seven of nine assays at the
low (range 23e47%, mean 36.6%) and the high (range
23e47%, mean 39%) concentrations, respectively. Indo-
methacin down-regulated the expression of IL-6 in four of
eight assays (range 28e46%, mean 38%), while in one
case it caused statistically signiﬁcant induction of IL-6 pro-
duction (34%). Paracetamol had no signiﬁcant effect on
IL-6 levels [Fig. 2(B)].
Like IL-6, all NSAIDs at the low and the high concentra-
tions reduced the levels of the TNF-a [Fig. 2(C)]. Aceclofe-
nac down-regulated the expression of TNF-a in six (range
11e31.5%, mean 22.3%) and seven (range 9e27.9%,
mean 20.7%) of nine assays at the low and the high con-
centrations, respectively. Piroxicam down-regulated the ex-
pression of TNF-a in four of nine assays at both
concentrations (range 20e24.8%, mean 22% for the low
and range 24e33%, mean 35.6% for the high concentra-
tion). However, piroxicam at the low concentration caused
also a statistically signiﬁcant induction of TNF-a production
in two of nine assays (range 21e22%, mean 21.5%). Te-
noxicam down-regulated the expression of TNF-a in six
(range 14e35%, mean 24.2%) and seven (range
11.7e32%, mean 22.6%) of nine assays at the low and
the high concentrations, respectively. Indomethacin down-
regulated the expression of TNF-a in six of eight assays
(range 11e39%, mean 21.7%). Unexpectedly, such an ef-
fect upon TNF-a was observed with the ‘‘neutral’’ drug para-
cetamol as well, in ﬁve of eight samples (range 19e35%,
mean 26%).
EFFECT OF NSAIDs ON PGE2 PRODUCTION
All the tested NSAIDs, as it was expected, had a potent
and pronounced inhibitory effect on PGE2 production in all
cases. The percentages at the low and the high concentra-
tions of drugs, respectively, ranged between 78e99.3 and
81.8e99.3 for aceclofenac, 84.7e98.3 and 87e99.4 for pir-
oxicam, 88.2e99.2 and 89.5e99.4 for tenoxicam and
90.4e99.4 for indomethacin, obviously of high statistical
signiﬁcance (Table I). The high expression of PGE2 in our
samples is worth noting and conﬁrms the activated state of
the IFTs. Paracetamol had no consistent effect on PGE2
levels. It showed a mild inhibitory effect on PGE2 production
in four of eight cases (range 13.2e61.5%, mean 39.8%),
while in another three cases showed a signiﬁcant stimula-
tory effect (range 16.9e96.3%, mean 54.5%) (Table I).
EFFECT OF NSAIDs ON GELATINOLYTIC (MMP-2 AND MMP-9)
ACTIVITY
Samples of conditioned media were subjected to gelatin
zymography (Fig. 3). The electrophoretic mobility of the gel-
atin lysis bands is shown, both under control conditions and
under the inﬂuence of the various NSAIDs. All specimens
contained four major gelatin lysis bands. From their electro-
phoretic mobility pattern, it is concluded that these bands
correspond to the MMP-9 proenzyme (proMMP-9), the par-
tially activated form of MMP-9 (act MMP-9), the MMP-2 pro-
enzyme (proMMP-2) and the activated form of MMP-2 (act
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Inhibition (%) of PGE2 production by 3-day explant cultures of IFT caused by NSAIDs
Patient Ace 1
(4 mg/ml)
Ace 2
(10 mg/ml)
Pir 1
(3 mg/ml)
Pir 2
(10 mg/ml)
Ten 1
(6 mg/ml)
Ten 2
(13 mg/ml)
Ind
(0.5 mg/ml)
Par
(10 mg/ml)
1 94.7 93.5 89 87.2 92.1 89.6 92.5 2.2 not
2 99.3 99.3 98.3 99.4 99.2 99.4 99.4 61.5
3 98.1 98.4 96.4 98.3 97.4 97.8 98.3 13.2
4 96 95 96.4 97 95.8 97 98 45.8
5 92.2 93.8 92.1 94.9 96 96.1 e e
6 78 81.8 85.3 87 88.2 89.5 90.4 50.4[
7 99 99.1 e e e e e e
8 98.7 98.8 94.6 98.4 95.1 98.2 98.5 38.7
9 92.3 92.5 94.9 95.1 94.2 94.5 91.4 16.9[
10 94.2 96.2 84.7 95.6 94.3 90.9 95.9 96.3[
Mean 94.3 94.8 92.8 94.8 94.7 94.8 95.6
Ace: Aceclofenac; Pir: Piroxicam; Ten: Tenoxicam; Ind: Indomethacin; Par: Paracetamol; by arrows ([) are indicated the samples where Par
caused induction. Not: not signiﬁcant.MMP-2), from top to bottom, respectively. Total MMP-9 ac-
tivity was calculated by adding the intensities of proMMP-9
and act MMP-9. Similarly, total MMP-2 activity was the sum
of the intensities of proMMP-2 and act MMP-2. As de-
scribed in Materials and methods section, the gelatinases’
speciﬁc activity was expressed in arbitrary units (pixels)
per gram of tissue wet weight and plotted in relation to
control (Fig. 4).
As shown in Fig. 4(A), all the tested NSAIDs did not differ
regarding signiﬁcant induction or inhibition on MMP-2 activ-
ity, which were both observed in relatively low percentages
(20e30%) of the samples. However, in four of nine cases
piroxicam and tenoxicam at the low and the high concentra-
tions, respectively, showed a stimulatory (range
32.4e93.6%, mean 56.2%) and an inhibitory (23e52.7%,
mean 34.1) effect. More inhibitory was the indomethacin,
causing an inhibition ranging from 21.5 to 63% with
a mean of 37.6% in 50% of assays.
Similar comments apply to MMP-9 speciﬁc activity
[Fig. 4(B)]. A drug associated inhibitory or stimulatory effect
was equally distributed in 45e60% of assays, while a lack of
effect occurred in the remaining 40e55%. However, piroxi-
cam at both concentrations was relatively more stimulatory,
causing stimulation of MMP-9 production in four of nine
cases (mean stimulation 48.6% and 62.4% at the low and
the high concentrations, respectively). On the other hand,
impressive was the inhibition of both gelatinases caused
by the ‘‘neutral’’ drug paracetamol. In ﬁve of eight cases it
showed an inhibitory effect on MMP-2 (range 13.6e63.7%,
mean 35.5%) and MMP-9 (range 13.8e56.3%, mean
32.7%) production, while only in two of eight cases it ex-
hibited a stimulatory effect on MMP-2 production (range
33e34.3%, mean 33.6%).
EFFECT OF NSAIDs ON MMP-1, MMP-3 AND MMP-13 LEVELS
The tendency of all NSAIDs, as far as signiﬁcant inhibi-
tion or induction upon MMP-1 and MMP-3 production was
concerned, was generally in favour of the former, albeit in
relatively small percentages of the samples, except for pir-
oxicam at the low concentration [Fig. 5(A,B)]. In particular,
aceclofenac at the low concentration exhibited an inhibitory
effect in three and two of nine cases (mean suppression 29
and 38.3%) on the production of MMP-1 and MMP-3, re-
spectively, while it exhibited a stimulatory effect in one
and two of nine cases (mean induction 36 and 32.6%) on
the production of MMP-1 and MMP-3, respectively. At thehigh concentration it exhibited an inhibitory effect in three
and two of nine cases (mean suppression 32.7 and
36.3%) on MMP-1 and MMP-3 production, respectively,
while it exhibited a stimulatory effect only in one of nine
cases (3%) on MMP-1 production. Piroxicam at the low con-
centration exhibited an inhibitory effect in two of nine cases
(mean suppression 38.8 and 31.3%) on the production of
MMP-1 and MMP-3, respectively, while it exhibited a stimu-
latory effect in four and two of nine cases (mean induction
19.3 and 44.6%) on MMP-1 and MMP-3 production, respec-
tively. At the high concentration it exhibited an inhibitory ef-
fect in ﬁve and three of nine cases (mean suppression 35.2
and 44.5%) on MMP-1 and MMP-3 production, respectively,
while it exhibited a stimulatory effect only in one of nine
cases (17.6%) on MMP-1 production. Tenoxicam at the
low concentration exhibited an inhibitory effect in three
and four of nine cases (mean suppression 40.9 and
43.1%) on the production of MMP-1 and MMP-3, respec-
tively, while it exhibited a stimulatory effect only in one of
nine cases (9.3 and 37.3%) on the production of MMP-1
and MMP-3, respectively. At the high concentration it ex-
hibited an inhibitory effect in four and two of nine cases
(mean suppression 24.6 and 40.7%) on MMP-1 and
MMP-3 production, respectively, while it exhibited a stimula-
tory effect only in one of nine cases (64.8%) on MMP-3 pro-
duction. Indomethacin exhibited an inhibitory effect in two of
eight cases (mean suppression 23.7 and 26.9%) on MMP-1
and MMP-3 production, respectively, while it exhibited
a stimulatory effect only in one of nine cases (9%) on
MMP-1 production. Paracetamol exhibited an inhibitory ef-
fect in four and three of eight cases (mean suppression
17.5 and 20.8%) on MMP-1 and MMP-3 production, respec-
tively, while it exhibited a stimulatory effect only in one of
the eight cases (31.4%) on MMP-3 production.
On the other hand, no deﬁnitive tendency was observed
regarding MMP-13 production [Fig. 5(C)]. All drugs exerted
a statistically signiﬁcant inhibitory (range 22.5e46.1%) or
stimulatory (range 20.5e53.7%) effect, equally distributed
in 35e55% of the experiments, while in the remaining
45e65% of the experiments they have no signiﬁcant effect.
Aceclofenac at high concentration would be an exemption
to the above, exhibiting a relatively inhibitory action. It
caused signiﬁcant inhibition in ﬁve of nine cases (mean sup-
pression 25.8%) and stimulation in two of nine cases (mean
induction 34.6%). Therefore, it cannot be clearly concluded,
whether there is an inhibitory or an inducing inﬂuence of the
drugs on the tested MMPs.
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A
B
C
D
E
proMMP-9
act MMP-9
proMMP-2
act MMP-2
proMMP-9
proMMP-9
proMMP-9
proMMP-9
act MMP-9
proMMP-2
act MMP-2
act MMP-9
proMMP-2
act MMP-2
act MMP-9
proMMP-2
act MMP-2
act MMP-9
proMMP-2
act MMP-2
Fig. 3. Representative gelatin zymographies of conditioned media obtained from 3-day explant culture of an IFT from hip arthroplasty, in the
absence or presence of NSAIDs. (A) Aceclofenac at concentrations 4 (lanes aec) and 10 (lanes def) mg/ml, (B) piroxicam at concentrations 3
(lanes aec) and 10 (lanes def) mg/ml, (C) tenoxicam at concentrations 6 (lanes aec) and 13 (lanes def) mg/ml, (D) indomethacin at concen-
tration 0.5 mg/ml (lanes aec) and paracetamol at concentration 10 mg/ml (lanes def), and (E) controls without drugs. The conditioned media
from three independent experiments with each drug concentration were run in duplicate. proMMP-9, proenzyme of MMP-9; act MMP-9, par-
tially activated form of MMP-9; proMMP-2, proenzyme of MMP-2; act MMP-2, activated form of MMP-2.
538 S. A. Syggelos et al.: NSAIDs effects on endoprostheses looseningEFFECT OF NSAIDs ON TIMP-1 AND TIMP-2 LEVELS
A tendency, of all NSAIDs tested, towards stimulation of
TIMP-1 production was observed [Fig. 6(A)]. Aceclofenac
in three of eight cases exhibited a stimulatory effect
(mean induction 81.6 and 68.3%) at the low and the high
concentrations, respectively, while it exhibited an inhibitory
effect in one and two of eight cases (mean suppression 77
and 52.3%) at the low and the high concentrations, respec-
tively. Piroxicam in four and three of eight cases exhibited
a stimulatory effect (mean induction 88.2 and 122%) at
the low and the high concentrations, respectively, while it
exhibited an inhibitory effect in one and two of eight cases
(mean suppression 57 and 55%) at the low and the high
concentrations, respectively. Tenoxicam in four and three
of eight cases exhibited a stimulatory effect (mean induction
100 and 113.7%) at the low and the high concentrations, re-
spectively, while it exhibited an inhibitory effect in one and
two of eight cases (mean suppression 63.5 and 41.6%) at
the low and the high concentrations, respectively. Indo-
methacin and paracetamol exhibited a stimulatory effect in
two of eight cases (mean induction 116.5 and 199%),
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Fig. 4. Metalloproteinase MMP-2 (A) and MMP-9 (B) activity in con-
ditioned media obtained from 3-day explant cultures of IFT from hip
(circle symbols) or knee (square symbols) arthroplasty, in the ab-
sence or presence of drugs. Closed symbols represent a statistically
signiﬁcant difference between NSAID exposed and unexposed cul-
tures (P< 0.05). The abbreviations for NSAIDs and their concentra-
tions used are as in Fig. 2.respectively, while they exhibited an inhibitory effect in
one of eight cases (47.6 and 65.6%), respectively.
The effect of almost all drugs upon TIMP-2 was similar
[Fig. 6(B)]. They showed no signiﬁcant effect in 40e65%
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Fig. 5. Levels of MMP-1 (A), MMP-3 (B) and MMP-13 (C) in condi-
tioned media obtained from 3-day explant cultures of IFT from hip
(circle symbols) or knee (square symbols) arthroplasty, in the ab-
sence or presence of drugs. Closed symbols represent a statistically
signiﬁcant difference between NSAID exposed and unexposed cul-
tures (P< 0.05). The abbreviations for NSAIDs and their concentra-
tions used are as in Fig. 2.
539Osteoarthritis and Cartilage Vol. 15, No. 5of the experiments, while in the remaining 35e60% of the
experiments, an equally distributed inhibition (range
20.8e34.9%) or induction (range 28.2e91.1%) occurred.
Discussion
The introduction of total joint arthroplasties, during the
last 40 years, has offered to those patients with destructive
arthritis free and painless movement. Unfortunately, loosen-
ing of joint implants, which may ensue after 1e20 or even
more years, has created a new problem for them and the
surgeons.
As it has already been mentioned, several cytokines,
such as IL-1b, IL-6 and TNF-a, proteolytic enzymes, such
as MMPs, and prostanoids, such as PGE2, play a key
role in the biological part of loosening pathogenesis. At
the same time, these speciﬁc factors may be also impli-
cated in the process of bone resorption. Consequently,
loosening is commonly combined with excessive osteolysis,
a fact that makes the revision surgery more complicated.
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Fig. 6. Levels of TIMP-1 (A) and TIMP-2 (B) in conditioned media
obtained from 3-day explant cultures of IFT from hip (circle sym-
bols) or knee (square symbols) arthroplasty, in the absence or pres-
ence of drugs. Closed symbols represent a statistically signiﬁcant
difference between NSAID exposed and unexposed cultures
(P< 0.05). The abbreviations for NSAIDs and their concentrations
used are as in Fig. 2.In our experiments we tested four well-known NSAIDs
(aceclofenac, piroxicam, tenoxicam and indomethacin)
and paracetamol (as ‘‘neutral’’ drug) for a possible effect
upon the IFT-induced in vitro production of the cytokines
IL-1b, IL-6 and TNF-a, the gelatinases MMP-2 and MMP-
9, the interstitial collagenases MMP-1 and MMP-13, the
stromelysin MMP-3, the tissue inhibitors of metalloprotei-
nases TIMP-1 and TIMP-2 and the prostaglandin PGE2. If
a favourable effect of these drugs could be established in vi-
tro upon the key players in the loosening process, in vivo
trials would be justiﬁed.
All the tested NSAIDs, as expected, caused a potent in-
hibition of PGE2 (range between 78.0% and 99.0%). Para-
cetamol did not have an analogous effect. Therefore,
theoretically the inhibition of PGE2, which may be impli-
cated in the process of loosening and osteolysis, by the
NSAIDs, would be expected to be beneﬁcial2.
Our ﬁndings regarding the major pro-inﬂammatory and
osteolysis favouring cytokines were interesting. All the
tested drugs exerted uniformly an inhibitory effect on IL-6
and TNF-a, while they did not affect the IL-1b production
or, in several samples, they exhibited a stimulatory effect,
mainly at high concentrations. Although all NSAIDs caused
a potent inhibition of PGE2, they had different effects on the
cytokine production, indicating that these effects may not
relate to the reduction of PGE2 levels. This point of view
is supported by the observation that paracetamol, which
did not affect the PGE2 production, caused signiﬁcant re-
duction of TNF-a levels. It seems that the mechanism of
NSAIDs action is more complicated and not only restricted
to the inhibition of cyclooxygenases.
The effect of NSAIDs on the IL-6 production in IFT cul-
tures has not been reported previously, although several in-
vestigators have tested this effect on synovial membrane,
cartilage and chondrocyte cultures. It has been reported
that all the tested drugs (except piroxicam) inhibit the IL-6
production in chondrocyte cultures, whereas meloxicam
and indomethacin induce IL-6 in cultures of synovial tis-
sue38,39. The above results support the hypothesis that
the NSAIDs may have differential effects, tissue and cell
type related. However, the possibility of the inhibitory effect
of NSAIDs upon IL-6 being partially mediated by their
known action on PGE2 production cannot be excluded,
since it has been reported that PGE2 induces the synthesis
of IL-6 by synovial ﬁbroblasts and osteoblasts40e45.
Regarding TNF-a and in agreement with our results, it
has been published already that piroxicam and indometha-
cin can decrease its levels in periprosthetic tissues26.
Furthermore, aceclofenac can inhibit the Lipopolysaccha-
ride-induced TNF-a production by synovial membranes46.
In our study the unexpected signiﬁcant inhibitory effect of
the ‘‘neutral’’ drug paracetamol on TNF-a is interesting
and needs further investigation.
Contrary to the ﬁndings described above about IL-6 and
TNF-a, all the tested drugs exerted a stimulatory effect on
the production of IL-1b in an adequate proportion of the
samples, more prominent at the high concentrations and
mainly with aceclofenac. An inhibitory effect of tenoxicam
and indomethacin, upon this cytokine, was also observed
in a small proportion of the samples. According to previ-
ously published studies, meloxicam did not affect the IL-1
production by synovial membrane, while piroxicam (10 mg/
ml) either increased or did not affect the IL-1 production
by IFT in equal proportion of samples (30%) and decreased
this in 40% of them26,38. This reported stimulatory effect of
piroxicam is comparable to the observed one in the present
study. Aceclofenac either did not affect or induce IL-1b
540 S. A. Syggelos et al.: NSAIDs effects on endoprostheses looseningproduction in synovial membrane cultures46. It has been
previously reported that prostaglandins decrease the IL-1b
production by macrophages, thus, an increase of IL-1b
levels by NSAIDs, through inhibition of prostaglandins,
would be expected, as has been previously observed by in-
domethacin47,48. Nevertheless, a partial suppression of IL-
1b production from blood cells by aceclofenac has been
reported49.
Since a lot of other factors, such as metalloproteinases,
are implicated in the loosening pathogenesis, the effect of
the NSAIDs on the most important of them was evaluated.
MMP-1, MMP-3, MMP-13 and the gelatinases (MMP-2 and
MMP-9) were chosen, because they have been clearly
identiﬁed in IFT1. Since MMPs become inactive, when cou-
pled with their inhibitors (TIMPs), the effect of NSAIDs on
TIMP production was also examined.
Although a rather inhibitory tendency of all the tested
NSAIDs was observed upon MMP-1 and MMP-3 produc-
tion, the direction was not clear, i.e., towards stimulation
or induction, in reference to the other MMPs. However,
again extremely interesting was the signiﬁcant inhibitory ef-
fect of the ‘‘neutral’’ drug paracetamol on the expression of
both gelatinases, MMP-2 and MMP-9. This, coupled with
a similar effect on TNF-a, needs further investigation and
suggests that this agent may not be a simple analgesic. Re-
garding TIMPs, all drugs seemed to induce TIMP-1 in a rel-
atively signiﬁcant proportion of the samples, while they did
not show a consistent effect on TIMP-2 production.
Given the stimulatory effect of NSAIDs on IL-1b produc-
tion and known that IL-1b induces the expression of several
MMPs, including MMP-1, MMP-3, MMP-9 and TIMP-1, as
well as, that PGE2 suppresses the IL-1b-induced production
of these MMPs by ﬁbroblasts and macrophages, a signiﬁ-
cant induction of MMPs by the NSAIDs would be ex-
pected28e30,50. The fact that this was not observed may
indicate a possible induction, by the NSAIDs, of another
factor that would antagonize the effect of IL-1b on MMPs.
A likely candidate for such an action would be Transforming
growth factor-b 1 (TGF-b1), which is expressed in IFT and is
known to suppress the IL-1b-stimulatory effect on the pro-
duction of MMP-1 and MMP-3, and this possibility remains
to be elucidated51,52e54. Regarding the observed TIMP-1
stimulation by the NSAIDs, this may be related to their sup-
pressive effect on PGE2 production and their stimulatory
effect on IL-1b. It has been reported that PGE2 suppressed
or did not inﬂuence IL-1b-stimulated TIMP-1 production in
human synovial ﬁbroblasts or macrophages50,55.
Summarizing our ﬁndings, in reference to the major pro-
inﬂammatory and osteolysis favouring cytokines, all the
tested drugs exerted uniformly an inhibitory effect on IL-6
and TNF-a, both known to directly cause osteoclastic
bone resorption, independently of PGE2
19e21. Moreover,
all of them reduced some MMPs and increased TIMP-1
levels in a signiﬁcant portion of samples, whereas in an-
other signiﬁcant portion they did not affect them. It is known
that MMPs induce and TIMPs suppress bone resorp-
tion18,56e58. Thus, considering the above observations, it
would be expected that the NSAIDs could reduce the ability
of periprosthetic membrane to cause bone resorption. In-
deed, it has been previously shown that piroxicam, which
exhibited about the same effects as the other tested
NSAIDs, signiﬁcantly decreased the IFT-induced resorptive
process26.
In conclusion, we can suggest that NSAIDs can possibly
retard the aseptic loosening, which complicates joint arthro-
plasty. However, this will depend on the net result of the
complex interplay between all the factors mentioned above,and probably others, not yet identiﬁed. Considering the
complexity of the pathogenetic mechanisms, we do not ex-
pect NSAIDs to solve the problem. Further studies in order
to identify the most important mediators in the resorption
and loosening processes are justiﬁed. Consequently,
in vivo long-termclinical trialsmay shed light on the possibility
of a beneﬁcial effect of speciﬁc NSAIDs on the loosening
process.
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